Amirali Moghaddam Sadegh

@ajums.ac.ir

Assistant Professor of Psychiatry, Department of Psychiatry, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz

Amirali Moghaddam Sadegh


               Download Compact PDF  
https://researchid.co/moghaddam.a
7

Scopus Publications

64

Scholar Citations

6

Scholar h-index

3

Scholar i10-index

Scopus Publications

  • Effectiveness of Ginseng on the Symptoms of Depression and Anxiety in Patients Referred to Addiction Treatment Clinics in Ahvaz: A Randomized Clinical Trial
    Seyede Fatemeh Mesbahi, Amirali Moghadam Sadegh, Esmaeil Mousavi Asl, Neda Sadrizadeh Irani, Hatam Boostani
    Jundishapur Journal of Natural Pharmaceutical Products, 2025
    Background: Anxiety and depression are significant factors that can increase the likelihood of concurrent substance use in patients undergoing treatment. Objectives: This study aims to address the gap in knowledge regarding the treatment of anxiety and depression resulting from substance withdrawal by evaluating the effectiveness of ginseng on depression and anxiety symptoms in patients at addiction treatment clinics in Ahvaz. Methods: This research is categorized as applied research and falls under experimental designs for data collection. It was a randomized clinical trial with a pre-test and post-test design involving two groups. The statistical population included all patients visiting addiction treatment clinics in Ahvaz during 2023 - 2024. A total of 68 participants meeting the inclusion and exclusion criteria were randomly assigned to two groups: One receiving ginseng and the other a placebo (34 participants each). One group received 100 mg capsules of ginseng, while the other received a placebo for four weeks. All participants were assessed at the beginning of the study and after the intervention using the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety Rating Scale (HARS). Data analysis was conducted using descriptive statistics and analysis of covariance, utilizing SPSS-26 software. Results: The study involved 68 individuals aged 28 to 59 years, with a mean age of 43.22 ± 8.89. The mean ± standard deviation of depression and anxiety in the pre-test of the intervention group was 29.85 ± 6.19 and 25.00 ± 6.06, respectively, and in the placebo group was 27.79 ± 7.21 and 23.91 ± 4.82, respectively. The mean ± standard deviation of depression and anxiety in the post-test of the intervention group was 15.44 ± 11.37 and 12.26 ± 10.40, respectively, and in the placebo group was 11.91 ± 10.83 and 13.32 ± 10.10, respectively. The results indicate no significant difference between post-test and pre-test scores in the intervention group compared to the placebo group (P > 0.05). Conclusions: The results indicate that there was no significant difference in post-test means compared to pre-test means in the intervention group relative to the placebo group. However, further randomized trials with larger sample sizes are necessary for confirmation. Findings should be interpreted with caution.
  • The Effectiveness of Transcranial Direct Current Stimulation (tDCS) on Severity of Obsessive-Compulsive Symptoms, Executive Functions and Rumination in People with Obsessive-Compulsive Symptoms: A Randomized Clinical Trial
    Mohammad Jahanseir, Esmaeil Mousavi Asl, Amirali Moghadam Sadegh, Ahmad Fakhri, Shahin Norouzi
    Jundishapur Journal of Chronic Disease Care, 2025
    Background: Medical and cognitive treatments for people with obsessive-compulsive symptoms have limitations. Concerns about obsessive-compulsive symptoms arise from evidence indicating that obsessive-compulsive disorder (OCD) can have severe psychological consequences. Objectives: This study aimed to investigate the effectiveness of transcranial direct current stimulation (tDCS) on the severity of obsessive-compulsive symptoms, executive functions, and rumination in individuals with obsessive-compulsive symptoms. Methods: This research was a randomized clinical trial with a pre-and post-test design involving two groups. The statistical population included all individuals with obsessive-compulsive symptoms who referred to the Golestan Hospital Psychiatry Clinic and the Jundishapur University of Medical Sciences Counseling Center in Ahvaz during 2022 - 2023. Thirty individuals who met the inclusion and exclusion criteria were randomly assigned to two groups. In this randomized controlled double-blind study, 30 participants with obsessive-compulsive symptoms (based on the Maudsley Questionnaire cut-off point of 11) were assigned to receive 10 sessions (one session per day) of either active tDCS (2 mA) or sham treatment. Of these, 15 participants received active tDCS, and 15 participants received sham treatment. At the beginning of the study and after the intervention, all subjects were assessed using the Maudsley Obsessional-Compulsive Questionnaire (MOCI), the Executive Functions Questionnaire, the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and the Mistake Rumination Scale. Data analysis included descriptive statistics and analysis of covariance, performed using SPSS-23 software. Results: In the pre-test, the mean scores of MOCI, Y-BOCS, mistake rumination, and executive functions in the active tDCS group were 22.40 ± 2.09, 22.33 ± 7.72, 20.93 ± 4.16, and 86.40 ± 14.38, respectively, compared to 21.53 ± 1.80, 20.33 ± 6.89, 19.13 ± 5.34, and 83.06 ± 16.61 in the sham treatment group. In the post-test, the mean scores in the active tDCS group were 14.46 ± 3.06, 14.40 ± 2.99, 11.46 ± 2.13, and 102.86 ± 8.40, respectively, compared to 21.66 ± 1.54, 18.13 ± 6.99, 18.26 ± 4.89, and 86.93 ± 15.54 in the sham treatment group. Results showed that the active tDCS group exhibited a significantly greater reduction in obsessive-compulsive symptoms and rumination and a significant improvement in executive functions compared to the sham treatment group (P < 0.05). Conclusions: The tDCS appears to have a significant effect on reducing obsessive-compulsive symptoms and rumination and improving executive functions in individuals with obsessive-compulsive symptoms. Longer treatment durations with a higher number of tDCS sessions may be necessary to achieve clinically significant responses. Additionally, determining the optimal electrode placement for OCD remains a critical and challenging issue.
  • The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial
    Amirali Moghaddam Sadegh, Masoumeh Nazarinasab, Forouzan Behrouzian, Hamzeh Rostami, Masoumeh Mehrabi
    Iranian Journal of Psychiatry, 2023
    Objective: Limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. Therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder.
 Methods: In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). The intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. The control group was treated with placebo. The duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. The Beck Depression Inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. The data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements.
 Results: There was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4th, 8th, and 12th weeks after the intervention (P > 0.05). The urine test also showed no significant difference between the two groups at any of the evaluation stages (P > 0.05). Although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2nd, 4th and 6th weeks (P > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8th, 10th, and 12th weeks (P < 0.05).
 Conclusion: Topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. However, further studies are needed to confirm these results.
  • Evaluating the Effect of Melatonin on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Placebo-Controlled Study
    Forouzan Behrouzian, Leila Abdi, Masoumeh Nazarinasab, Amirali Moghaddam Sadegh, Sanam Anoosheh, Maryam Moradi
    Iranian Journal of Psychiatry, 2023
    Objective: Schizophrenia is known as a severe psychiatric disorder with a broad range of clinical indications and symptoms such as positive and negative symptoms. This study was conducted with the aim of investigating the effect of melatonin on positive and negative symptoms of inpatients with schizophrenia.
 Method: This study was conducted as a randomized placebo-controlled trial (double-blind) in the population of patients with schizophrenia. Study samples were selected from inpatients with schizophrenia, according to the DSM-5 criteria, who had not been diagnosed with a depressive episode of schizophrenia based on the Calgary questionnaire and who also met the inclusion criteria. 46 patients with schizophrenia were randomly assigned to the intervention (6 mg melatonin per day as two 3 mg pills for six weeks) and placebo groups. The positive and negative symptom scale (PANSS) was used to assess the effect of treatment at T1 (before intervention), T2 (three weeks after beginning the intervention) and T3 (six weeks after beginning the intervention). To check the research hypotheses, multiple comparison statistics were used by the SPSS 22 software.
 Results: The placebo and melatonin groups had no significant difference in terms of PANSS scores (negative, positive, general and total symptom scores) at T1. Also, there was no difference in PANSS scores between the two groups at T2. However, at T3, there was a significant difference between the two groups only in the score of negative symptoms of PANSS (P = 0.036), so that negative symptoms of schizophrenia were significantly reduced in the intervention group compared to the placebo group. Furthermore, based on within-group analyzes, all PANSS scores were significantly reduced in the two groups at T2 and T3 (P < 0.05).
 Conclusion: Long-term use (at least six weeks) of melatonin can improve the negative symptoms of schizophrenia. Since antipsychotics can better affect the positive symptoms, the use of melatonin in combination with these drugs may perhaps further improve the patients’ symptoms.
  • Mediating Role of Self-esteem and Self-efficacy in the Relationship of Perfectionism and Negative Reactivity with Eating Disorders
    Esmaeil Mousavi Asl, Hamzeh Rostami, Amirali Moghadam Sadegh, Leila Abdi, Forouzan Behrouzian
    Iranian Journal of Psychiatry and Behavioral Sciences, 2022
    Background: Eating disorders (EDs) are prevalent in adolescents and young adults, leading to various psychiatric and physical complications that affect the quality of life and even mortality. Objectives: The present study aimed to investigate the mediating role of self-efficacy and self-esteem in the relationship of perfectionism and negative reactivity with EDs. Methods: This descriptive study was performed on 302 students selected from the University of Tehran during 2018 - 2019. The data collection tools were the ED Examination-Questionnaire Short form, Self-esteem Scale, Weight Efficacy Lifestyle Questionnaire‑Short Form, ED Inventory-Perfectionism Scale, and Perth Emotional Reactivity Scale. Pearson’s correlation coefficient and structural equation modeling were used to analyze the data. Results: The results showed that EDs had significant positive correlations with perfectionism (r = 0.4, P = 0.01) and general negative reactivity (r = 0.53, P = 0.01). On the other hand, these disorders had a significant negative correlation with self-esteem (r = -0.48, P = 0.01) and self-efficacy (r = 0.53, P=0.01). Self-esteem had a negative significant relationship with perfectionism (r = -0.12, P = 0.05) and negative reactivity (r = -0.68, P = 0.01). Moreover, self-efficacy had a negative significant relationship with perfectionism (r = -0.28, P = 0.01) and negative reactivity (r = -0.5, P = 0.01). The findings of path analysis showed that self-esteem and self-efficacy played mediating roles in the relationship of negative reactivity and perfectionism with EDs. Negative reactivity directly affected eating pathology (t = 1.27, ß = 0.13) but is not significant. Conclusions: Our findings showed that self-esteem and self-efficacy are protective factors against the negative effects of perfectionism and negative reactivity. Therefore, self-esteem and self-efficacy can be considered as parts of prevention and treatment programs for EDs.
  • Investigating the efficacy of Ginkgo biloba on the cognitive function of patients undergoing treatment with electric shock: a double-blind clinical trial
    M. Nazarinasab, F. Behrouzian, Saeedeh Negahban, A. Sadegh, Elham Zeynali
    Journal of Medicine and Life, 2022
    Cognitive impairment is common in patients undergoing electroconvulsive therapy (ECT). Researchers are seeking pharmaceutical compounds with low side effects to decrease these outcomes. This study aimed to investigate the effectiveness of Ginkgo biloba therapy on the cognitive function of patients treated with electroshock. In a double-blinded clinical trial, 80 patients with psychiatric disorders who were candidates for ECT in 2019 were randomly assigned to two groups: the intervention group (receiving Ginkgo biloba drug) and the control group (receiving placebo). We used the Mini-Mental State Examination (MMSE) and Wechsler Memory Scale Recipe III (WMS-III) questionnaires to evaluate the efficacy of the drug on the cognitive function at time 0, after 4 sessions and 72 hours post-final session of ECT. The data were analyzed by SPSS version 22, with a significance level of 0.05. Patients' assessment after the intervention showed that the average MMSE scores in the intervention group (28.92±1.04) were statistically higher than in the control group (27.85±1.56). The average scores of the WMS-III in the intervention group and the control group were 97.45±8.04 and 92.00±4.45 after 4 sessions of ECT, and 100.26±8.33 and 92.40±3.92 after the intervention (p=0.001). According to the findings, Gingko biloba increased MMSE and WMS-III scores in older patients (patients over 40 had better scores in both questionnaires, the drug was more effective, and with no side effects).
  • The mediating role of self-compassion in the relationship between positive reactivity, negative reactivity, and perfectionism with disordered eating
    Esmaeil Mousavi Asl, L. Abdi, Amirali Moghaddam Sadegh, F. Behrouzian
    Journal of Education and Health Promotion, 2021
    BACKGROUND: Individuals with disordered eating are at an increased of having one or more additional risks for comorbid disorders, such as anxiety disorder, depressive disorder, and insomnia. Therefore, the present study aimed to investigate the mediating role of self-compassion in the relationship between positive reactivity, negative reactivity, and perfectionism with disordered eating. MATERIALS AND METHODS: The study method was descriptive-correlational through structural equation modeling (SEM). The present study population included all students of the University of Tehran in the city of Tehran in 2018–2019. A total of 302 students were selected by convenience sampling method and completed questionnaires on eating attitudes test-8, self-compassion scale (short form), eating disorder inventory-perfectionism scale, and Perth emotional reactivity scale. The SEM path analysis and Pearson correlation coefficient were conducted to analyze the obtained data in SPSS-23 and Lisrel-8.80. RESULTS: The finding of the path analysis showed that self-compassion acts as a mediating role in the relationship of disordered eating with positive and negative emotional reactivity and perfectionism. Only the direct effect coefficient of general positive reactivity on disordered eating was not significant. CONCLUSION: Based on the results of this study, self-compassion can serve as a protective factor against negative emotional reactivity and perfectionism. Therefore, self-compassion can be considered in the development of prevention and treatment programs for disordered eating.

RECENT SCHOLAR PUBLICATIONS

  • The Effect of Zinc Supplementation on Relapse of Anxiety and Depression in Opioid-Dependent Patients Treated with Methadone
    AM Sadegh, S Norouzi, NS Irani, SEM Asl, SGK Mohammadi
    International Journal of High Risk Behaviors and Addiction 14 (14) , 2025
    2025
    Citations: 1
  • Effectiveness of Ginseng on the Symptoms of Depression and Anxiety in Patients Referred to Addiction Treatment Clinics in Ahvaz: A Randomized Clinical Trial
    SF Mesbahi, AM Sadegh, EM Asl, NS Irani, H Boostani
    Jundishapur Journal of Natural Pharmaceutical Products 20 (20) , 2025
    2025
  • The Effectiveness of Transcranial Direct Current Stimulation (tDCS) on Severity of Obsessive-Compulsive Symptoms, Executive Functions and Rumination in People with Obsessive …
    M Jahanseir, EM Asl, AM Sadegh, A Fakhri, S Norouzi
    Jundishapur Journal of Chronic Disease Care 14 (14) , 2025
    2025
    Citations: 1
  • The effectiveness of topiramate in the treatment of amphetamine and methamphetamine use disorder: a randomized controlled trial
    AM Sadegh, M Nazarinasab, F Behrouzian, H Rostami, M Mehrabi
    Iranian Journal of Psychiatry 18 (4), 371 , 2023
    2023
    Citations: 7
  • Evaluating the effect of melatonin on positive and negative symptoms of schizophrenic patients: a randomized placebo-controlled study
    F Behrouzian, L Abdi, M Nazarinasab, AM Sadegh, S Anoosheh, ...
    Iranian Journal of Psychiatry 18 (2), 119 , 2023
    2023
    Citations: 8
  • Investigating the efficacy of Ginkgo biloba on the cognitive function of patients undergoing treatment with electric shock: a double-blind clinical trial
    M Nazarinasab, F Behrouzian, S Negahban, AM Sadegh, E Zeynali
    Journal of Medicine and Life 15 (12), 1540 , 2022
    2022
    Citations: 5
  • Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
    F Behrouzian, M Nazarinasab, AM Sadegh, L Abdi, M Sabzevarizadeh
    Journal of Family Medicine and Primary Care 11 (12), 7795-7799 , 2022
    2022
    Citations: 10
  • Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
    M Nazarinasab, F Behrouzian, L Abdi, AAS Moghaddam, S Sadeghi
    Journal of Family Medicine and Primary Care 11 (12), 7800-7805 , 2022
    2022
    Citations: 14
  • Mediating role of self-esteem and self-efficacy in the relationship of perfectionism and negative reactivity with eating disorders
    EM Asl, H Rostami, AM Sadegh, L Abdi, F Behrouzian
    Iranian journal of psychiatry and behavioral sciences 16 (1), 1-6 , 2022
    2022
    Citations: 8
  • The mediating role of self-compassion in the relationship between positive reactivity, negative reactivity, and perfectionism with disordered eating
    EM Asl, L Abdi, AM Sadegh, F Behrouzian
    Journal of Education and Health Promotion 10, 249 , 2021
    2021
    Citations: 10
  • COMPARISON OF EFFICACY OF EXTENDED-RELEASE VENLAFAXINE VERSUS SERTRALINE IN TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    S Paksersht, H Boostani, AM Sadegh, M Haghdoost
    2016

MOST CITED SCHOLAR PUBLICATIONS

  • Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
    M Nazarinasab, F Behrouzian, L Abdi, AAS Moghaddam, S Sadeghi
    Journal of Family Medicine and Primary Care 11 (12), 7800-7805 , 2022
    2022
    Citations: 14
  • Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
    F Behrouzian, M Nazarinasab, AM Sadegh, L Abdi, M Sabzevarizadeh
    Journal of Family Medicine and Primary Care 11 (12), 7795-7799 , 2022
    2022
    Citations: 10
  • The mediating role of self-compassion in the relationship between positive reactivity, negative reactivity, and perfectionism with disordered eating
    EM Asl, L Abdi, AM Sadegh, F Behrouzian
    Journal of Education and Health Promotion 10, 249 , 2021
    2021
    Citations: 10
  • Evaluating the effect of melatonin on positive and negative symptoms of schizophrenic patients: a randomized placebo-controlled study
    F Behrouzian, L Abdi, M Nazarinasab, AM Sadegh, S Anoosheh, ...
    Iranian Journal of Psychiatry 18 (2), 119 , 2023
    2023
    Citations: 8
  • Mediating role of self-esteem and self-efficacy in the relationship of perfectionism and negative reactivity with eating disorders
    EM Asl, H Rostami, AM Sadegh, L Abdi, F Behrouzian
    Iranian journal of psychiatry and behavioral sciences 16 (1), 1-6 , 2022
    2022
    Citations: 8
  • The effectiveness of topiramate in the treatment of amphetamine and methamphetamine use disorder: a randomized controlled trial
    AM Sadegh, M Nazarinasab, F Behrouzian, H Rostami, M Mehrabi
    Iranian Journal of Psychiatry 18 (4), 371 , 2023
    2023
    Citations: 7
  • Investigating the efficacy of Ginkgo biloba on the cognitive function of patients undergoing treatment with electric shock: a double-blind clinical trial
    M Nazarinasab, F Behrouzian, S Negahban, AM Sadegh, E Zeynali
    Journal of Medicine and Life 15 (12), 1540 , 2022
    2022
    Citations: 5
  • The Effect of Zinc Supplementation on Relapse of Anxiety and Depression in Opioid-Dependent Patients Treated with Methadone
    AM Sadegh, S Norouzi, NS Irani, SEM Asl, SGK Mohammadi
    International Journal of High Risk Behaviors and Addiction 14 (14) , 2025
    2025
    Citations: 1
  • The Effectiveness of Transcranial Direct Current Stimulation (tDCS) on Severity of Obsessive-Compulsive Symptoms, Executive Functions and Rumination in People with Obsessive …
    M Jahanseir, EM Asl, AM Sadegh, A Fakhri, S Norouzi
    Jundishapur Journal of Chronic Disease Care 14 (14) , 2025
    2025
    Citations: 1
  • Effectiveness of Ginseng on the Symptoms of Depression and Anxiety in Patients Referred to Addiction Treatment Clinics in Ahvaz: A Randomized Clinical Trial
    SF Mesbahi, AM Sadegh, EM Asl, NS Irani, H Boostani
    Jundishapur Journal of Natural Pharmaceutical Products 20 (20) , 2025
    2025
  • COMPARISON OF EFFICACY OF EXTENDED-RELEASE VENLAFAXINE VERSUS SERTRALINE IN TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    S Paksersht, H Boostani, AM Sadegh, M Haghdoost
    2016